Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Title: Clinical trial availability and receipt of guideline concordant care among adolescents and young adults (AYAs) with acute lymphoblastic leukemia

Julie Wolfson, Michelle Nuno, Abbie Kleckley et al. Nov 03, 2025 pp. 6190-6190 10.1182/blood-2025-6190

Abstract BACKGROUND: Adolescents and young adults (AYA: 15-39y) with acute lymphoblastic leukemia (ALL) face poor survival with minimal hist...

Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication

Pierre Bories, Mojca Jongen-Lavrencic, Laimonas Griškevičius et al. Nov 03, 2025 pp. 3419-3419 10.1182/blood-2025-3419

Abstract BACKGROUND: MP0533 is a tetra-specific CD3-engaging DARPin designed for avidity-driven T cell-mediated killing of acute myeloid leuk...

Outcomes in children and adolescents with down syndrome and B-lymphoblastic leukemia: A report from Children's oncology group study AALL1731

Amanda Li, John Kairalla, Cindy Wang et al. Nov 03, 2025 pp. 547-547 10.1182/blood-2025-547

Abstract Background: Individuals with DS have a 20-fold increased risk of B-ALL, and experience increased rates of both relapse and treatmen...

Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506

Sameem Abedin, Victor Baidoo, Anikó Szabó et al. Nov 03, 2025 pp. 170-170 10.1182/blood-2025-170

Abstract INTRODUCTION Allogeneic hematopoietic cell transplantation (alloHCT) is indicated in patients (pts) with FLT3-ITD mutated AML. The...

Caplacizumab as a single agent without plasma exchange in relapsed and refractory thrombotic thrombocytopenic purpura: A systematic review.

Bibi Maryam, Abdul Manaf, Dee Terrell-Schnorrenberg et al. Nov 03, 2025 pp. 3116-3116 10.1182/blood-2025-3116

Abstract Introduction: Caplacizumab is an anti-von Willebrand factor nanobody that has transformed the treatment landscape of thrombotic thro...

Real-world outcomes of primary gastric diffuse large B cell lymphoma in Latin America: A multicenter cohort from the grupo de estudio latinoamericano de linfoproliferativos (GELL)

Rafael Pichardo-Rodriguez, Brady Beltran, Luis Mario Villela Martinez et al. Nov 03, 2025 pp. 5451-5451 10.1182/blood-2025-5451

Abstract INTRODUCTION: Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is a rare and heterogeneous entity within extranodal non-Hod...

Current practices, organizational structures, technologies and challenges in developing atmps: A survey by dare-NL, nxtgen hightech, T2EVOLVE and ctiwp of EBMT - a gocart-coalition initiative

Anil Deshantri, Simone Punt, Ganesh Ramesh et al. Nov 03, 2025 pp. 5961-5961 10.1182/blood-2025-5961

Abstract Introduction The path from academic development of Advanced Therapy Medicinal Products (ATMPs) to marketing authorization remains c...

Nfkb signaling in idecabtagene vicleucel infusion product drives response in relapsed/refractory multiple myeloma

Jerald Noble, Barbara Peixoto, Meghan Menges et al. Nov 03, 2025 pp. 504-504 10.1182/blood-2025-504

Abstract Background: B-cell maturation antigen (BCMA) directed chimeric antigen receptor T-cell (CAR-T) therapy has revo...

Venetoclax-based regimens are non-inferior to chemotherapy in core binding factor AML, including AML1-ETO

Yu Wu, Lei Zhao, Yufei Yang et al. Nov 03, 2025 pp. 6965-6965 10.1182/blood-2025-6965

Abstract Background Core binding factor acute myeloid leukemia (CBF-AML) is a favorable-risk molecular subtype defined by the presence of ei...

Longitudinal quality improvement curriculum for hematology/oncology fellows in an academic training program

Michael Keng, Michael Douvas, Gautham Prakash et al. Nov 03, 2025 pp. 4645-4645 10.1182/blood-2025-4645

Abstract Background: Quality improvement (QI) is a critical component of medicine and an Accreditation Council for Gradu...

The global PNH patient registry:  real-world data on PNH symptom burden and quality of life

David Araten, Austin Kulasekararaj, Jun-ichi Nishimura et al. Nov 03, 2025 pp. 2697-2697 10.1182/blood-2025-2697

Abstract Introduction: Current knowledge of the lived experience of individuals with Paroxysmal Nocturnal Hemoglobinuria (PNH) is informed b...

Clinical features and outcomes of adult T-cell leukemia/lymphoma across world regions: An international retrospective cohort study

Bryan Valcarcel, Haruhiko Sano, Atae Utsunomiya et al. Nov 03, 2025 pp. 3636-3636 10.1182/blood-2025-3636

Abstract Background: Adult T-cell leukemia/lymphoma (ATL) has a dismal prognosis and disproportionately affects regions endemic in Human T-ly...

Updated Results from a Phase 1b study of olverembatinib (HQP1351) combined with lisaftoclax (APG-2575) in pediatric patients with relapsed/refractory Philadelphia Chromosome–Positive acute lymphoblastic leukemia

Jingliao Zhang, Junxia Wang, Huanshan Guo et al. Nov 03, 2025 pp. 6876-6876 10.1182/blood-2025-6876

Abstract Background Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) in pediatric patients remains a high-risk subtyp...

Next generation platelet storage bags for better and safer transfusions

Nicolas Pereyra, Jose Alvarez, Parisa Golesorkhi et al. Nov 03, 2025 pp. 545-545 10.1182/blood-2025-545

Abstract Platelet transfusion is a lifesaving medical procedure in contexts ranging from hemorrhagic bleeding to chemotherapy. However, plat...

The efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma: A retrospective real-world study

Shunfeng Hu, Beibei Lv, Ya Zhang et al. Nov 03, 2025 pp. 7111-7111 10.1182/blood-2025-7111

Abstract Background: Bruton's tyrosine kinase (BTK), a pivotal regulator of B-cell receptor (BCR) signaling, plays a critical role in the su...

Marrow-ly we learn along: A needs assessment of the educational needs of pediatric and young adult patients with bone marrow failure

Sara Bowman, Jill de Jong, Jessie Alexander et al. Nov 03, 2025 pp. 2861-2861 10.1182/blood-2025-2861

Abstract Diagnoses of bone marrow failure (BMF), whether acquired or inherited, are rare. The incidence of idiopathic aplastic anemia, the m...

Iptacopan monotherapy demonstrated improved clinical outcomes in a real-world cohort with paroxysmal nocturnal hemoglobinuria: Evidence from a managed access program

Silvia Sanz, Abdulfaheem Khan, Sviatlana Rizk et al. Nov 03, 2025 pp. 3202-3202 10.1182/blood-2025-3202

Abstract Background: Iptacopan, the first-in-class oral complement factor B inhibitor that selectively inhibits the alternative pathway of th...

Telomere attrition is common in patients with germline RUNX1 pathogenic variants

Rialnat Lawal, Fernanda Gutierrez-Rodrigues, David Young et al. Nov 03, 2025 pp. 4991-4991 10.1182/blood-2025-4991

Abstract Introduction Familial platelet disorder with associated myeloid malignancy (FPDMM) is a rare, autosomal dominant hematologic malign...

Blood microbial DNA as a non-invasive diagnostic surrogate for pneumonia pathogens in immunocompromised patients: A real-world outcomes analysis

Kun Zhou, Xianmin Song Nov 03, 2025 pp. 4204-4204 10.1182/blood-2025-4204

Abstract While blood testing is a non-invasive tool for pneumonia diagnosis, its utility depends on specific clinical conditions. Given the...

Characterizing differences in CAR-T cell therapy outcomes based on sex in patients with large B-cell lymphoma

John Behman, Muhammad Bilal Abid Nov 03, 2025 pp. 1948-1948 10.1182/blood-2025-1948

Abstract Background: Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated improved survival in patients with relapsed, refracto...

The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) suppresses IL-8 and other pro-inflammatory cytokines in patients with low-risk myelodysplastic syndrome and symptomatic anemia

Devan Bursey, Victoria Allgood, Andrea Groen et al. Nov 03, 2025 pp. 2092-2092 10.1182/blood-2025-2092

Abstract Background Chronic inflammation is a key driver of disease progression in myelodysplastic syndromes (MDS), contributing to ineffect...

Psychometric evaluation of the self-management skills checklist across Brazil and the United States: Toward global measurement of transition readiness in sickle cell disease

Kelly Pimenta, Alejandro Vázquez, Patricia Moura et al. Nov 03, 2025 pp. 1186-1186 10.1182/blood-2025-1186

Abstract Background: The transition from pediatric to adult care is a critical period of vulnerability for adolescents and young adults (AYA...

Outcomes of stem cell transplantation in pediatric and adolescent/young adult patients with trisomy 21: A single-center experience

Maria Frost, Olayinka Okeleji, Demetrios Petropoulos et al. Nov 03, 2025 pp. 7742-7742 10.1182/blood-2025-7742

Abstract Background: For patients with Trisomy 21/Down Syndrome (DS), advances in chemotherapy regimens have increased the 5-year overall su...

A parsimonious, clinically-interpretable logistic model for anemia in PLWHA: Feature selection with MCP penalization and validation in a retrospective cohort

Jingwen Zhang, Xiaoyan Lv, Junfeng Huo et al. Nov 03, 2025 pp. 7987-7987 10.1182/blood-2025-7987

Abstract Background:Anemia remains a common comorbidity in persons living with HIV/AIDS (PLWHA). Among people infected with HIV, anemia is a...

Incidence and characteristics of myeloid neoplasms in patients with multiple myeloma treated with novel myeloma-directed therapies

Benedetto Bruno, Aurora Martin, Chiara Caredda et al. Nov 03, 2025 pp. 3990-3990 10.1182/blood-2025-3990

Abstract BackgroundTherapy-related myeloid neoplasms (t-MNs), including therapy-related myelodysplastic syndromes (t-MDS) and acute myeloid...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page